• 00:30 1.
    index 1
  • 00:26 2.
    Breast Cancer
  • 00:32 3.
    Triple-Negative Breast Cancer(TNBC)
  • 00:36 4.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:17 5.
    Circular RNA (CircRNA)
  • 00:26 6.
    Functions of circRNA
  • 00:31 7.
    MicroRNA (miRNA)
  • 00:40 8.
    Aim
  • 00:59 9.
    The expression and prognostic significance of circWAC in TNBC
  • 01:12 10.
    Features of circWAC
  • 00:42 11.
    CircWAC was mainly distributed in the cytoplasm
  • 00:38 12.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:43 13.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 01:11 14.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:39 15.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 01:31 16.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:29 17.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 01:04 18.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:28 19.
    CircWAC regulates PTX resistance by targeting miR-142
  • 01:12 20.
    WWP1 is the direct target gene of miR-142
  • 00:58 21.
    WWP1 is the direct target gene of miR-142
  • 01:28 22.
    WWP1 is the direct target gene of miR-142
  • 00:30 23.
    The expression and prognostic significance of circWAC in TNBC
  • 01:22 24.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:33 25.
    Conclusion
  • 01:02 26.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:22 27.
    Thank you for listening.
  • 00:08 28.
    Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
  • 00:00 29.
    PI3K/AKT pathway
  • 00:03 30.
    Slide 29
  • 00:00 31.
    CircWAC had no obvious relationship with cell metastasis and invasion
  • 00:00 32.
    Thank you for listening.
  • 00:00 33.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:00 34.
    Conclusion
  • 00:00 35.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 36.
    The expression and prognostic significance of circWAC in TNBC
  • 00:22 37.
    WWP1 is the direct target gene of miR-142
  • 00:06 38.
    WWP1 is the direct target gene of miR-142
  • 01:57 39.
    WWP1 is the direct target gene of miR-142
  • 00:02 40.
    Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
  • 00:00 41.
    PI3K/AKT pathway
  • 00:00 42.
    Slide 29
  • 00:00 43.
    CircWAC had no obvious relationship with cell metastasis and invasion
  • 00:00 44.
    Thank you for listening.
  • 00:00 45.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:00 46.
    Conclusion
  • 00:00 47.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 48.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 49.
    WWP1 is the direct target gene of miR-142
  • 00:00 50.
    WWP1 is the direct target gene of miR-142
  • 00:00 51.
    WWP1 is the direct target gene of miR-142
  • 00:00 52.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:03 53.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 54.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 55.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 56.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:33 57.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 58.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 59.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 60.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 61.
    Features of circWAC
  • 00:00 62.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 63.
    Aim
  • 00:00 64.
    MicroRNA (miRNA)
  • 00:00 65.
    Functions of circRNA
  • 00:00 66.
    Circular RNA (CircRNA)
  • 00:00 67.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:32 68.
    Triple-Negative Breast Cancer(TNBC)
  • 00:29 69.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:02 70.
    Circular RNA (CircRNA)
  • 00:08 71.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:04 72.
    Circular RNA (CircRNA)
  • 01:10 73.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 74.
    Circular RNA (CircRNA)
  • 00:03 75.
    Functions of circRNA
  • 00:01 76.
    Circular RNA (CircRNA)
  • 00:00 77.
    Functions of circRNA
  • 00:07 78.
    MicroRNA (miRNA)
  • 00:21 79.
    Functions of circRNA
  • 00:00 80.
    MicroRNA (miRNA)
  • 01:03 81.
    Aim
  • 00:04 82.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 83.
    Features of circWAC
  • 00:00 84.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 85.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:01 86.
    CircWAC was mainly distributed in the cytoplasm
  • 00:21 87.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 88.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 89.
    Features of circWAC
  • 00:04 90.
    The expression and prognostic significance of circWAC in TNBC
  • 00:28 91.
    Features of circWAC
  • 00:50 92.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 93.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 94.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:14 95.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 96.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 97.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 98.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 99.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 100.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 101.
    WWP1 is the direct target gene of miR-142
  • 00:00 102.
    WWP1 is the direct target gene of miR-142
  • 00:01 103.
    WWP1 is the direct target gene of miR-142
  • 00:24 104.
    WWP1 is the direct target gene of miR-142
  • 00:09 105.
    WWP1 is the direct target gene of miR-142
  • 00:00 106.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 107.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:44 108.
    Conclusion
  • 01:20 109.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:00 110.
    Conclusion
  • 00:00 111.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 112.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 113.
    WWP1 is the direct target gene of miR-142
  • 00:00 114.
    WWP1 is the direct target gene of miR-142
  • 00:00 115.
    WWP1 is the direct target gene of miR-142
  • 00:00 116.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 117.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 118.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 119.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 120.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 121.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 122.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 123.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 124.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 125.
    Features of circWAC
  • 00:00 126.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 127.
    Aim
  • 00:00 128.
    MicroRNA (miRNA)
  • 00:00 129.
    Functions of circRNA
  • 00:00 130.
    Circular RNA (CircRNA)
  • 00:00 131.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 132.
    Triple-Negative Breast Cancer(TNBC)
  • 00:53 133.
    Breast Cancer
  • 00:01 134.
    Triple-Negative Breast Cancer(TNBC)
  • 00:03 135.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:02 136.
    Circular RNA (CircRNA)
  • 00:00 137.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:04 138.
    Triple-Negative Breast Cancer(TNBC)
  • 00:25 139.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:09 140.
    Triple-Negative Breast Cancer(TNBC)
  • 00:00 141.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:07 142.
    Circular RNA (CircRNA)
  • 01:37 143.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 144.
    Circular RNA (CircRNA)
  • 00:01 145.
    Functions of circRNA
  • 00:00 146.
    Circular RNA (CircRNA)
  • 00:04 147.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 148.
    Circular RNA (CircRNA)
  • 00:02 149.
    Functions of circRNA
  • 00:00 150.
    MicroRNA (miRNA)
  • 00:12 151.
    Functions of circRNA
  • 00:00 152.
    Circular RNA (CircRNA)
  • 00:13 153.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 154.
    Circular RNA (CircRNA)
  • 00:00 155.
    Functions of circRNA
  • 00:01 156.
    MicroRNA (miRNA)
  • 00:02 157.
    Aim
  • 00:05 158.
    MicroRNA (miRNA)
  • 00:00 159.
    Functions of circRNA
  • 00:00 160.
    Circular RNA (CircRNA)
  • 00:54 161.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 01:34 162.
    Triple-Negative Breast Cancer(TNBC)
  • 00:07 163.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:15 164.
    Circular RNA (CircRNA)
  • 00:00 165.
    Functions of circRNA
  • 00:00 166.
    MicroRNA (miRNA)
  • 01:18 167.
    Aim
  • 00:08 168.
    The expression and prognostic significance of circWAC in TNBC
  • 01:19 169.
    Features of circWAC
  • 00:00 170.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 171.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 172.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:31 173.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 174.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 175.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 176.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 177.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 178.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 179.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 180.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 181.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 182.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 183.
    WWP1 is the direct target gene of miR-142
  • 00:00 184.
    WWP1 is the direct target gene of miR-142
  • 00:00 185.
    WWP1 is the direct target gene of miR-142
  • 00:00 186.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 187.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 188.
    Conclusion
  • 00:53 189.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:00 190.
    Conclusion
  • 00:00 191.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 192.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 193.
    WWP1 is the direct target gene of miR-142
  • 00:00 194.
    WWP1 is the direct target gene of miR-142
  • 00:00 195.
    WWP1 is the direct target gene of miR-142
  • 00:00 196.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 197.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 198.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 199.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 200.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:05 201.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:03 202.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:01 203.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:03 204.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:18 205.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 206.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 207.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 208.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 209.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 210.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 211.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 212.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 213.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:02 214.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 215.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 216.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 217.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 218.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:30 219.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 220.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 221.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 222.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 223.
    Features of circWAC
  • 00:00 224.
    The expression and prognostic significance of circWAC in TNBC
  • 00:01 225.
    Aim
  • 00:12 226.
    MicroRNA (miRNA)
  • 00:00 227.
    Functions of circRNA
  • 00:00 228.
    Circular RNA (CircRNA)
  • 01:16 229.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 00:00 230.
    Triple-Negative Breast Cancer(TNBC)
  • 00:00 231.
    Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
  • 01:28 232.
    Circular RNA (CircRNA)
  • 00:01 233.
    Functions of circRNA
  • 00:00 234.
    MicroRNA (miRNA)
  • 00:00 235.
    Aim
  • 00:00 236.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 237.
    Features of circWAC
  • 00:00 238.
    CircWAC was mainly distributed in the cytoplasm
  • 00:00 239.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 240.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 241.
    CircWAC decrease chemosensitivity to PTX in TNBC
  • 00:00 242.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 243.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 244.
    CircWAC acts as a sponge of miR-142 in TNBC
  • 00:00 245.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 246.
    CircWAC regulates PTX resistance by targeting miR-142
  • 00:00 247.
    WWP1 is the direct target gene of miR-142
  • 00:00 248.
    WWP1 is the direct target gene of miR-142
  • 00:00 249.
    WWP1 is the direct target gene of miR-142
  • 00:00 250.
    The expression and prognostic significance of circWAC in TNBC
  • 00:00 251.
    Inhibition of circWAC increases sensitivity to PTX in vivo
  • 00:00 252.
    Conclusion
  • 06:17 253.
    Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
  • 00:42 254.
    ** after 20221101 林俐妤seminar.pptx
  • Index
  • Notes
  • Comment
  • Fullscreen
20221031_lab meeting_俐妤
Duration: 56:45, Browse: 92, Last Updated: 2022-10-31
    Prev Next
    • 00:30 1.
      index 1
    • 00:26 2.
      Breast Cancer
    • 00:32 3.
      Triple-Negative Breast Cancer(TNBC)
    • 00:36 4.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:17 5.
      Circular RNA (CircRNA)
    • 00:26 6.
      Functions of circRNA
    • 00:31 7.
      MicroRNA (miRNA)
    • 00:40 8.
      Aim
    • 00:59 9.
      The expression and prognostic significance of circWAC in TNBC
    • 01:12 10.
      Features of circWAC
    • 00:42 11.
      CircWAC was mainly distributed in the cytoplasm
    • 00:38 12.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:43 13.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 01:11 14.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:39 15.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 01:31 16.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:29 17.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 01:04 18.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:28 19.
      CircWAC regulates PTX resistance by targeting miR-142
    • 01:12 20.
      WWP1 is the direct target gene of miR-142
    • 00:58 21.
      WWP1 is the direct target gene of miR-142
    • 01:28 22.
      WWP1 is the direct target gene of miR-142
    • 00:30 23.
      The expression and prognostic significance of circWAC in TNBC
    • 01:22 24.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:33 25.
      Conclusion
    • 01:02 26.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:22 27.
      Thank you for listening.
    • 00:08 28.
      Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
    • 00:00 29.
      PI3K/AKT pathway
    • 00:03 30.
      Slide 29
    • 00:00 31.
      CircWAC had no obvious relationship with cell metastasis and invasion
    • 00:00 32.
      Thank you for listening.
    • 00:00 33.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:00 34.
      Conclusion
    • 00:00 35.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 36.
      The expression and prognostic significance of circWAC in TNBC
    • 00:22 37.
      WWP1 is the direct target gene of miR-142
    • 00:06 38.
      WWP1 is the direct target gene of miR-142
    • 01:57 39.
      WWP1 is the direct target gene of miR-142
    • 00:02 40.
      Model for WWP1-mediated PTEN K27-linked polyubiquitination in tumor development and progression
    • 00:00 41.
      PI3K/AKT pathway
    • 00:00 42.
      Slide 29
    • 00:00 43.
      CircWAC had no obvious relationship with cell metastasis and invasion
    • 00:00 44.
      Thank you for listening.
    • 00:00 45.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:00 46.
      Conclusion
    • 00:00 47.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 48.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 49.
      WWP1 is the direct target gene of miR-142
    • 00:00 50.
      WWP1 is the direct target gene of miR-142
    • 00:00 51.
      WWP1 is the direct target gene of miR-142
    • 00:00 52.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:03 53.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 54.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 55.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 56.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:33 57.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 58.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 59.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 60.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 61.
      Features of circWAC
    • 00:00 62.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 63.
      Aim
    • 00:00 64.
      MicroRNA (miRNA)
    • 00:00 65.
      Functions of circRNA
    • 00:00 66.
      Circular RNA (CircRNA)
    • 00:00 67.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:32 68.
      Triple-Negative Breast Cancer(TNBC)
    • 00:29 69.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:02 70.
      Circular RNA (CircRNA)
    • 00:08 71.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:04 72.
      Circular RNA (CircRNA)
    • 01:10 73.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 74.
      Circular RNA (CircRNA)
    • 00:03 75.
      Functions of circRNA
    • 00:01 76.
      Circular RNA (CircRNA)
    • 00:00 77.
      Functions of circRNA
    • 00:07 78.
      MicroRNA (miRNA)
    • 00:21 79.
      Functions of circRNA
    • 00:00 80.
      MicroRNA (miRNA)
    • 01:03 81.
      Aim
    • 00:04 82.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 83.
      Features of circWAC
    • 00:00 84.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 85.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:01 86.
      CircWAC was mainly distributed in the cytoplasm
    • 00:21 87.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 88.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 89.
      Features of circWAC
    • 00:04 90.
      The expression and prognostic significance of circWAC in TNBC
    • 00:28 91.
      Features of circWAC
    • 00:50 92.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 93.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 94.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:14 95.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 96.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 97.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 98.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 99.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 100.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 101.
      WWP1 is the direct target gene of miR-142
    • 00:00 102.
      WWP1 is the direct target gene of miR-142
    • 00:01 103.
      WWP1 is the direct target gene of miR-142
    • 00:24 104.
      WWP1 is the direct target gene of miR-142
    • 00:09 105.
      WWP1 is the direct target gene of miR-142
    • 00:00 106.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 107.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:44 108.
      Conclusion
    • 01:20 109.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:00 110.
      Conclusion
    • 00:00 111.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 112.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 113.
      WWP1 is the direct target gene of miR-142
    • 00:00 114.
      WWP1 is the direct target gene of miR-142
    • 00:00 115.
      WWP1 is the direct target gene of miR-142
    • 00:00 116.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 117.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 118.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 119.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 120.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 121.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 122.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 123.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 124.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 125.
      Features of circWAC
    • 00:00 126.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 127.
      Aim
    • 00:00 128.
      MicroRNA (miRNA)
    • 00:00 129.
      Functions of circRNA
    • 00:00 130.
      Circular RNA (CircRNA)
    • 00:00 131.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 132.
      Triple-Negative Breast Cancer(TNBC)
    • 00:53 133.
      Breast Cancer
    • 00:01 134.
      Triple-Negative Breast Cancer(TNBC)
    • 00:03 135.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:02 136.
      Circular RNA (CircRNA)
    • 00:00 137.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:04 138.
      Triple-Negative Breast Cancer(TNBC)
    • 00:25 139.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:09 140.
      Triple-Negative Breast Cancer(TNBC)
    • 00:00 141.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:07 142.
      Circular RNA (CircRNA)
    • 01:37 143.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 144.
      Circular RNA (CircRNA)
    • 00:01 145.
      Functions of circRNA
    • 00:00 146.
      Circular RNA (CircRNA)
    • 00:04 147.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 148.
      Circular RNA (CircRNA)
    • 00:02 149.
      Functions of circRNA
    • 00:00 150.
      MicroRNA (miRNA)
    • 00:12 151.
      Functions of circRNA
    • 00:00 152.
      Circular RNA (CircRNA)
    • 00:13 153.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 154.
      Circular RNA (CircRNA)
    • 00:00 155.
      Functions of circRNA
    • 00:01 156.
      MicroRNA (miRNA)
    • 00:02 157.
      Aim
    • 00:05 158.
      MicroRNA (miRNA)
    • 00:00 159.
      Functions of circRNA
    • 00:00 160.
      Circular RNA (CircRNA)
    • 00:54 161.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 01:34 162.
      Triple-Negative Breast Cancer(TNBC)
    • 00:07 163.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:15 164.
      Circular RNA (CircRNA)
    • 00:00 165.
      Functions of circRNA
    • 00:00 166.
      MicroRNA (miRNA)
    • 01:18 167.
      Aim
    • 00:08 168.
      The expression and prognostic significance of circWAC in TNBC
    • 01:19 169.
      Features of circWAC
    • 00:00 170.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 171.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 172.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:31 173.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 174.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 175.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 176.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 177.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 178.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 179.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 180.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 181.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 182.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 183.
      WWP1 is the direct target gene of miR-142
    • 00:00 184.
      WWP1 is the direct target gene of miR-142
    • 00:00 185.
      WWP1 is the direct target gene of miR-142
    • 00:00 186.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 187.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 188.
      Conclusion
    • 00:53 189.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:00 190.
      Conclusion
    • 00:00 191.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 192.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 193.
      WWP1 is the direct target gene of miR-142
    • 00:00 194.
      WWP1 is the direct target gene of miR-142
    • 00:00 195.
      WWP1 is the direct target gene of miR-142
    • 00:00 196.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 197.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 198.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 199.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 200.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:05 201.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:03 202.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:01 203.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:03 204.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:18 205.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 206.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 207.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 208.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 209.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 210.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 211.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 212.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 213.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:02 214.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 215.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 216.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 217.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 218.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:30 219.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 220.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 221.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 222.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 223.
      Features of circWAC
    • 00:00 224.
      The expression and prognostic significance of circWAC in TNBC
    • 00:01 225.
      Aim
    • 00:12 226.
      MicroRNA (miRNA)
    • 00:00 227.
      Functions of circRNA
    • 00:00 228.
      Circular RNA (CircRNA)
    • 01:16 229.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 00:00 230.
      Triple-Negative Breast Cancer(TNBC)
    • 00:00 231.
      Paclitaxel(PTX) is frequently used as the first-line treatment drug in BC.Chemoresistance is a major problem of cancer treatment associated with poor response.Mechanism of action of PTX
    • 01:28 232.
      Circular RNA (CircRNA)
    • 00:01 233.
      Functions of circRNA
    • 00:00 234.
      MicroRNA (miRNA)
    • 00:00 235.
      Aim
    • 00:00 236.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 237.
      Features of circWAC
    • 00:00 238.
      CircWAC was mainly distributed in the cytoplasm
    • 00:00 239.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 240.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 241.
      CircWAC decrease chemosensitivity to PTX in TNBC
    • 00:00 242.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 243.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 244.
      CircWAC acts as a sponge of miR-142 in TNBC
    • 00:00 245.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 246.
      CircWAC regulates PTX resistance by targeting miR-142
    • 00:00 247.
      WWP1 is the direct target gene of miR-142
    • 00:00 248.
      WWP1 is the direct target gene of miR-142
    • 00:00 249.
      WWP1 is the direct target gene of miR-142
    • 00:00 250.
      The expression and prognostic significance of circWAC in TNBC
    • 00:00 251.
      Inhibition of circWAC increases sensitivity to PTX in vivo
    • 00:00 252.
      Conclusion
    • 06:17 253.
      Pros: They clearly discovered the network between circWAC and miR-142 using tissue samples from TNBC patients and databases. This research included an in vivo experiment to demonstrate how circWAC inhibition can improve chemosensitivity to PTX.They discov
    • 00:42 254.
      ** after 20221101 林俐妤seminar.pptx
    Location
    1. Media Center
    2. ...
    3. 2022
    Folder name
    2022
    Author
    林俐妤
    Branch
    賴亮全教授
    Created
    2022-10-31 11:50:39
    Last Updated
    2022-10-31 14:25:09
    Browse
    92
    Duration
    56:45

    臺北市仁愛路一段1號10樓1009室

    R1009 10F No1 Sec1 Ren-Ai Rd, Taipei 100233, Taiwan.

    E-mail: llai@ntu.edu.tw

    Tel: 886-2-2312-3456 # 288241

    Lab: 886-2-2393-8235